ReviewCancer innovation2023

Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.

Ziyi Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.